戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ate, cysteine, glutamine, lysine, malate and pyroglutamate.
2  equilibrium is strongly in the direction of pyroglutamate.
3  were blocked by cyclization of glutamine to pyroglutamate.
4 N-terminal residue was glutamine rather than pyroglutamate.
5 %), and a compound tentatively identified as pyroglutamate (22%).
6                                              Pyroglutamate-3 amyloid-B (pGlu3 AB) is an N-terminally
7                Among PTM-Abeta variants, the pyroglutamate-3-Abeta ((pyro)E3-Abeta) has attracted muc
8 dialysis, radioactivity was recovered in 14C-pyroglutamate (88%) and 14C-glutamine (11%).
9                    However, it confirms that pyroglutamate, a known constituent in brain, is actively
10 uctures for TAP01 family antibodies bound to pyroglutamate AB3-14, we identified a novel pseudo B-hai
11 42 and AB1-40 - and the N-truncated species, pyroglutamate AB3-42 and AB4-42, which appear to play a
12 o improving mAb specificity and affinity for pyroglutamate Abeta.
13                   N-terminally truncated and pyroglutamated Abeta peptides were recently shown to see
14 -length Abeta1-42 and Abeta1-40, N-truncated pyroglutamate Abeta3-42 and Abeta4-42 are major variants
15 a starting with position four in addition to pyroglutamate Abeta3-x is a relevant target to fight Alz
16 ith both the free N-terminus of Abeta4-x and pyroglutamate Abeta3-X mitigated neuron loss in Tg4-42 m
17                                 NT4X reduced pyroglutamate Abeta3-x, Abetax-40 and Thioflavin-S posit
18 ed higher levels of Abeta1-40 and N-terminal pyroglutamated Abetax-42 compared to diffuse plaques and
19 observed that diffuse plaques have increased pyroglutamated Abetax-42 levels in s-AD but not CU-AP, s
20 e for the removal of pyroglutamate (pGlu) by pyroglutamate aminopeptidase (PGAP) and demonstrate its
21 in chains of immunoglobulins with the enzyme pyroglutamate aminopeptidase requires the use of chaotro
22                   Following injection of 14C-pyroglutamate and microdialysis, radioactivity was recov
23 w peptide is: [sequence: see text] where Z = pyroglutamate and O = 4-trans-hydroxyproline.
24 KD and 12 matched healthy subjects) received pyroglutamated apelin-13 ([Pyr(1)]apelin-13, 1 nmol/min
25       The prevalence and biological roles of pyroglutamate are little understood, in part due to limi
26 studies indicated that 14C-glutamine and 14C-pyroglutamate are not subject to significant non-enzymat
27 gical roles of some PTMs, such as N-terminal pyroglutamate, are poorly understood due to a dearth of
28            Our data do not support a role of pyroglutamate as an intermediate in the formation of ext
29 eavy chains of immunoglobulins such that the pyroglutamate at the amino terminal was accessible to en
30 anslationally modified Abeta peptides with a pyroglutamate at the N-terminus (pGlu3, pE3), are attrac
31 Amyloid-beta (Abeta) peptides, starting with pyroglutamate at the third residue (pyroGlu-3 Abeta), ar
32 mab (an antibody specific for the N-terminal pyroglutamate beta-amyloid epitope) dosing was every 4 w
33 l peptide mapping step for identification of pyroglutamate-blocked N-terminal peptides.
34                     In one of these changes, pyroglutamate can form on the N terminus of the polypept
35 stage diversification of biologically active pyroglutamate-containing sequences.
36 t ADan-(1-34) and its N-terminally modified (pyroglutamate) counterpart together with Abeta-(1-42) an
37 um l-pyroglutamate (l-MSpG) and monosodium d-pyroglutamate (d-MSpG).
38 d an improved method for the halogenation of pyroglutamate derivatives in high yield with enhanced st
39              Reverse microdialysis with 1 mM pyroglutamate did not increase interstitial glutamate le
40 n this study, we determined if non-enzymatic pyroglutamate formation from glutamine contributed to th
41  deamidation in the Fc domain and N-terminal pyroglutamate formation in the heavy chain are the main
42 tion in the Fc domain, and 10-15% N-terminal pyroglutamate formation in the heavy chain.
43                                              Pyroglutamate formation increases the rate of Abeta olig
44                                              Pyroglutamate formation was additionally found to increa
45 oxicity of Abeta3-40 and Abeta3-42 and their pyroglutamated forms.
46                    Typically, the removal of pyroglutamate from the protein chains of immunoglobulins
47 -Ala-Thr-Lys-Lys-Pro-Tyr-Ile-Leu-OH, pGlu is pyroglutamate) from Conus geographus venom.
48  for direct labeling and identification of a pyroglutamate hormone present in porcine intestinal extr
49 he N terminus, which can be cyclized to form pyroglutamate in mammalian cells, the IL17A neutralizati
50 f anticancer activity through the N-terminal pyroglutamate in naturally occurring asperigimycins C an
51       Cyclization of N-terminal glutamine to pyroglutamate is a common modification of recombinant mo
52                                              Pyroglutamate is a cyclic N-terminal post-translational
53                                 Methyl N-Boc-pyroglutamate is cleaved with vinylmagnesium bromide to
54                                              Pyroglutamate is in chemical equilibrium with glutamate,
55 mi intensity were identified as monosodium l-pyroglutamate (l-MSpG) and monosodium d-pyroglutamate (d
56                                              Pyroglutamate levels increased over time after injection
57                                              Pyroglutamate-modified Abeta peptides at amino acid posi
58                                              Pyroglutamate-modified amyloid-beta (pE-Abeta) is a high
59                                              Pyroglutamate-modified amyloid-beta (pEAbeta) has been d
60 oredox catalysis process that enables direct pyroglutamate N-H arylation in peptides and proteins, us
61 ic conversion of the N-terminal glutamine to pyroglutamate not only provides an identification of the
62                      Glutamate conversion to pyroglutamate occurs more slowly than from glutamine but
63                             The NH2-terminal pyroglutamate of onconase, a residue essential for ribon
64 erminal cyclization of glutamine residues to pyroglutamate on the light and heavy chains are the majo
65 t against oligomeric assemblies of Abeta and pyroglutamate or oxidized residues, and IgGs specific fo
66 onal antibodies can cyclize spontaneously to pyroglutamate (pE) in vitro.
67                  Cyclization of Gln1 to form pyroglutamate (pE) limited the site of cross-linking in
68 o and in vivo Because N-terminally truncated pyroglutamate (pE)-modified Abeta species (AbetapE3) exh
69                             Juxtaposition of pyroglutamate pE3 and the F4 side chain (the "pEF head")
70 cine comprising two Abeta peptides (1-14 and pyroglutamate pE3-14) and three tau peptides (centered o
71 , PFA1 binds the toxic N-terminally modified pyroglutamate peptide pyro-Glu3-Abeta with a 77-fold los
72 rt an optimized procedure for the removal of pyroglutamate (pGlu) by pyroglutamate aminopeptidase (PG
73                                              Pyroglutamate (pGlu), a cyclization product of N-termina
74 eine and glutamate residues and results in a pyroglutamate product.
75 sultant N-terminal glutamine was cyclized to pyroglutamate (pyrGln(23)), and several C-terminal pepti
76 ue disulfide connectivity, and an N-terminal pyroglutamate rendered copsin extremely stable against h
77 bohydrate group, and the identification of a pyroglutamate residue at the sequence N-terminus.
78 the blocked CHH suggests that the N-terminal pyroglutamate residue has no obvious biological signific
79 teine residues is evident but the N-terminal pyroglutamate residue is replaced by a six-residue exten
80 evealing that the function of the N-terminal pyroglutamate residue is to secure Lys9.
81                    Selective modification of pyroglutamate residues in complex polypeptides may provi
82 ts provide the first chemical tool to modify pyroglutamate residues within complex polypeptides in bi
83 ed successfully to facilitate the removal of pyroglutamate residues.
84 ogical tools to label, quantify, or identify pyroglutamate residues.
85 ed peptides that is selective for N-terminal pyroglutamate residues.
86 )]Ser or [Met-(-1)]Tyr instead of the native pyroglutamate results in recombinant onconase derivative
87 lective annulation of an oxolane ring onto a pyroglutamate scaffold to construct either a gamma,gamma
88 th the native protein lacking the N-terminal pyroglutamate (the numbering system used has Asp2 as the
89 characterized by cyclization of glutamine to pyroglutamate; the N-terminus of ZP2 was identified by E
90 ated bicyclic lactam substrates derived from pyroglutamate using aqueous hydrogen peroxide and tertia
91 erase to convert the N-terminal glutamine to pyroglutamate was developed in the current study.
92 ost-translational modification, glutamate to pyroglutamate, was not present in soluble circulating AD
93  terminus was post-translationally modified (pyroglutamate), whereas Abeta was mainly Abeta-(4-42).